← Leaderboards
Paul Stephen Keim
Northern Arizona University
$16,650,291
Attributed
$16,650,291
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,868,473 · 10
By mechanism
U19$9,968,518 · 3
U01$7,549,272 · 2
R01$5,713,063 · 2
U54$1,646,782 · 1
R21$990,838 · 2
Top collaborators
No co-investigators on record.
Most similar at Northern Arizona University
Same institution · by research overlap
- Erik W Settles$1,421,853
Others in their field
Top investigators on “Virulence”
- Ronald B Corley · Boston University Medical Campus$43,000,000
- Joseph Heitman · Duke University$29,765,716
- Vanessa Sperandio · University Of Wisconsin-Madison$29,177,087
- Adolfo Garcia-Sastre · Jackson Laboratory$28,883,338
- John J Mekalanos · Harvard Medical School$28,747,360
- Scott J Hultgren · Washington University$28,322,020
Research focus
VirulenceDiagnosticPathogenDesignGenesInfectionCollectionGene ExpressionGenomicsArizonaCommunitiesBaseProgramsPerformanceTechnologyInstitutionResearch PersonnelBioinformaticsNucleic AcidsSamplingLaboratoriesCollaborationsRepositoryDetection
Grant awards (38)
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis$1,530,461
U19 · FY2025 · AI · contact PI
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis$344,960
U19 · FY2025 · AI · contact PI
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis$1,474,679
U19 · FY2024 · AI · contact PI
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis$1,416,075
U19 · FY2024 · AI · contact PI
Early in vivo expressed antigens and their role in virulence, immune response, and vaccines for coccidioidomycosis$227,047
U19 · FY2024 · AI · contact PI
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis$1,542,693
U19 · FY2023 · AI · contact PI
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis$1,390,215
U19 · FY2023 · AI · contact PI
Early in vivo expressed antigens and their role in virulence, immune response, and vaccines for coccidioidomycosis$258,366
U19 · FY2023 · AI · contact PI
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis$1,519,099
U19 · FY2022 · AI · contact PI
Early in vivo expressed antigens and their role in virulence, immune response, and vaccines for coccidioidomycosis$264,923
U19 · FY2022 · AI · contact PI
Molecular Antibiotic Resistance Arrays for clinical microbiology laboratories$868,077
R01 · FY2014 · AI · contact PI
Molecular Antibiotic Resistance Arrays for clinical microbiology laboratories$960,677
R01 · FY2013 · AI · contact PI
Genomic Correlates with Differential Virulence in Melioidosis Animal Models$312,933
U54 · FY2013 · AI · contact PI
Functional genomic analyses of emerging Cryptococcus subtypes in North America$226,142
R21 · FY2013 · AI · contact PI
Molecular Antibiotic Resistance Arrays for clinical microbiology laboratories$978,843
R01 · FY2012 · AI · contact PI
Genomic Correlates with Differential Virulence in Melioidosis Animal Models$320,303
U54 · FY2012 · AI · contact PI
Functional genomic analyses of emerging Cryptococcus subtypes in North America$291,179
R21 · FY2012 · AI · contact PI
Molecular Antibiotic Resistance Arrays for clinical microbiology laboratories$889,235
R01 · FY2011 · AI · contact PI
Burkholderia: International Collaborative Development of Novel Diagnostics$886,515
U01 · FY2011 · AI · contact PI
Genomic Correlates with Differential Virulence in Melioidosis Animal Models$346,045
U54 · FY2011 · AI · contact PI
Burkholderia: International Collaborative Development of Novel Diagnostics$927,361
U01 · FY2010 · AI · contact PI
Molecular Antibiotic Resistance Arrays for clinical microbiology laboratories$875,000
R01 · FY2010 · AI · contact PI
Genomic Correlates with Differential Virulence in Melioidosis Animal Models$333,826
U54 · FY2010 · AI · contact PI
Genomic-based diagnostics for Coccidioides the causative agent of Valley fever$207,506
R21 · FY2010 · AI · contact PI
Burkholderia: International Collaborative Development of Novel Diagnostics$912,735
U01 · FY2009 · AI · contact PI
Real-Time PCR Assays for Direct Detection of Sepsis and CAP Pathogens$626,212
U01 · FY2009 · AI · contact PI
Genomic Correlates with Differential Virulence in Melioidosis Animal Models$333,675
U54 · FY2009 · AI · contact PI
Genomic-based diagnostics for Coccidioides the causative agent of Valley fever$266,011
R21 · FY2009 · AI · contact PI
Burkholderia: International Collaborative Development of Novel Diagnostics$889,317
U01 · FY2008 · AI · contact PI
Real-Time PCR Assays for Direct Detection of Sepsis and CAP Pathogens$607,974
U01 · FY2008 · AI · contact PI
Burkholderia: International Collaborative Development of Novel Diagnostics$897,681
U01 · FY2007 · AI · contact PI
Real-Time PCR Assays for Direct Detection of Sepsis and CAP Pathogens$601,699
U01 · FY2007 · AI · contact PI
Real-Time PCR Assays /Direct Detection of Sepsis /CAP Pa$601,622
U01 · FY2006 · AI · contact PI
Real-Time PCR Assays /Direct Detection of Sepsis /CAP Pa$598,156
U01 · FY2005 · AI
ANTHRAX MOLECULAR EVOLUTION, DIVERSITY AND EPIDEMIOLOGY$290,343
R01 · FY2003 · GM
ANTHRAX MOLECULAR EVOLUTION, DIVERSITY AND EPIDEMIOLOGY$284,723
R01 · FY2002 · GM
ANTHRAX MOLECULAR EVOLUTION, DIVERSITY AND EPIDEMIOLOGY$282,924
R01 · FY2001 · GM
ANTHRAX MOLECULAR EVOLUTION, DIVERSITY AND EPIDEMIOLOGY$283,241
R01 · FY2000 · GM